Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
Public ClinicalTrials.gov record NCT00054795. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase III Trial of Xcytrin® (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.
Study identification
- NCT ID
- NCT00054795
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 550 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- May 8, 2007
United States locations
- U.S. sites
- 44
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Fort Smith | Arkansas | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Berkeley | California | — | — |
| Not listed | Concord | California | — | — |
| Not listed | Greenbrae | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Montebello | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Stanford | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Hartford | Connecticut | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Fort Wayne | Indiana | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Washington D.C | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Grand Rapids | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Camden | New Jersey | — | — |
| Not listed | Morristown | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Hershey | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Laredo | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Charlottesville | Virginia | — | — |
| Not listed | Madison | Wisconsin | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00054795, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2007 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00054795 live on ClinicalTrials.gov.